|
1）Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001; 47: 673-80
|
|
|
|
2）Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008; 141(4): 413-22
|
|
|
|
|
3）Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23(2): 215-24
|
|
|
|
|
|
4）Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003; 361(9356): 489-91
|
|
|
|
|
|
5）Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002; 48: 1437-44
|
|
|
|
|
|
6）Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammo-pathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006; 81: 1575-8
|
|
|
|
|
|
7）Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106(3): 812-7
|
|
|
|
|
|
8）Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111(2): 785-9
|
|
|
|
|
|
9）Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006; 108: 1979-83
|
|
|
|
|
|
10）Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum-free light chain ratio in patients with newly diagnosed myeloma and proposed incorporation into the International Staging System. Leukemia. 2008; 22: 1933-7
|
|
|
|
|
|
11）van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007; 110: 827-32
|
|
|
|
|
|
12）Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010; 116(24): 5126-9
|
|
|
|
|
|
13）Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011; 86: 251-5
|
|
|
|
|
|
14）Kuhnemund A, Liebisch P, Bauchmuller K, et al. ʻLight-chain escape-multiple myeloma-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009; 135(3): 477-84
|
|
|
|
|
|
15）Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011; 29(12): 1627-33
|
|
|
|
|
|
16）Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011; 29(12): 1620-6
|
|
|
|
|
|
17）Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011; 118(10): 2821-6
|
|
|
|
|
|
18）Thompson CA, Maurer MJ, Cerhan JR, et al. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol. 2011; 86(12): 998-1000
|
|
|
|
|
|
19）Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012; 30: 1087-94
|
|
|
|
|
|
20）Khanim FL, Merrick BAME, Giles HV, et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer Journal. 2011; 1: e39
|
|
|
|
|